Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?
The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.
Overview
The short, but glib, answer to the headline question posed for Viking Therapeutics (NASDAQ: VKTX) investors is "no," because the likelihood is that the $4.6 billion market cap company will be bought up by a larger pharmaceutical company if it has success in its clinical trials, and particularly with its lead drug candidate VK2735. Still, that doesn't mean the company can't deliver substantial value to investors. Here's why.
VK2735 is a dual GLP-1/GIP agonist in development for weight loss and diabetes management. It's part of a growing and popular class of drugs that already dominate the weight loss market, thanks to blockbuster drugs like Eli Lilly's (NYSE: LLY) Zepbound (tirzepatide) and Novo Nordisk's (NYSE: NVO) Wegovy (semaglutide).
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.